about
The Role of Galectin-3 in the KidneysRisk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-AnalysisChronic kidney disease care delivered by US family medicine and internal medicine trainees: results from an online survey.Evaluation of risk factor management of patients treated on an internal nephrology ward: a pilot studyRenin-Angiotensin System Inhibitor is Associated with Lower Risk of Ensuing Chronic Kidney Disease after Functional Recovery from Acute Kidney Injury.Predicting the risk of chronic Kidney Disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores.Ignoring the obvious missing piece of chronic kidney disease in HIV: cigarette smoking.A simple algorithm to predict incident kidney disease.Risk factors for chronic kidney disease: an updateCardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort study.Lessons from the profile of kidney diseases among Afghan refugees.[Profile of diabetic in chronic hemodialysis: a multicenter study in Morocco]Identification of modifiable chronic kidney disease risk factors by gender in an African-American metabolic syndrome cohort.Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general populationPerformance of a genetic risk score for CKD stage 3 in the general populationEarly chronic kidney disease: diagnosis, management and models of careGalectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal DamageLiterature Review and Profile of Cancer Diseases Among Afghan Refugees in Iran: Referrals in Six Years of Displacement.Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3The role of renin-angiotensin-aldosterone system genes in the progression of chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).Increased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients.Elevated galectin-3 precedes the development of CKDPublic health surveillance of CKD: principles, steps, and challenges.Effect of shared care on blood pressure in patients with chronic kidney disease: a cluster randomised controlled trial.Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors.On the occasion of world kidney day 2017; obesity and its relationship with chronic kidney diseaseThe timing of dialysis initiation affects the incidence of renal replacement therapy.New ways of working; delivering better care for people with long-term conditions.Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy.Factors affecting conformity to renin-angiotensin system inhibitor usage in chronic kidney disease and diabetes mellitus.Independent Contributions of Obstructive Sleep Apnea and the Metabolic Syndrome to the Risk of Chronic Kidney Disease.A simple prediction score for kidney disease in the Korean population.Effects of Chronic Ochratoxin A Exposure on p53 Heterozygous and p53 Homozygous Mice.Association of endothelial nitric oxide synthase gene intron 4 polymorphism with end-stage renal disease.Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007–2011The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial
P2860
Q26752754-9D6AAAEF-9909-45B3-B498-F460EB2C957AQ26764823-524A4E85-92A4-4591-92A8-71775F4B8957Q33266310-ED547F19-343A-4413-B2A5-E2EF2DE676C8Q33500377-B34E1F8D-144F-4BDA-8EA5-C56D90A97F92Q33559888-AEA93E71-616E-4F89-8753-8B2CF582E644Q33611383-A9AC2D6C-3EDC-43FF-AE97-3E6FCE5C0EAEQ33636234-8DF89C6A-058B-4B3A-9DB9-AAE04F7062BAQ33771352-5845C931-C87E-48EE-9DED-35889BE3E680Q33873248-6F55878E-4FA4-4957-81FF-80DB676A59CEQ33950911-2C289D9B-BC50-41F4-8DAE-0DC727825AC7Q34211499-8A2AD07F-1EA0-41FC-896E-9BCFCCB0D5C4Q34444873-EE00718E-BFFD-4735-AAA2-CBB2F9C2051DQ34936443-0E71849C-862D-41C0-B9E0-B003005810E5Q35000389-18FBDBA0-2799-42A0-93BC-43A0E203AA0AQ35624242-ED79E2CA-7C09-440E-A7EE-4BE2B5B8A0C5Q35938045-75396F40-4CC9-4D53-958B-1DD9BEA7289CQ36187612-57F32001-F918-4E09-BCB4-1A92F31CF9F1Q36325646-967ACE34-CC1F-43E1-A74F-C4CBEDA7EBA4Q36602500-9A78996B-08F1-4CA1-98C5-E87B48E9884FQ36816871-F9EA8695-1F10-4FE7-8206-00209B1A7D4EQ36877214-740F4AE4-60BB-4A91-AA70-CFA88312A3E7Q36950161-43DC488A-BCF0-4A3E-AB32-DD0CB01FF48FQ37119904-03D319AD-EDB2-4754-AC26-EF5D2D68E9E2Q37187226-77684D54-9281-44DE-8855-483FDACED81DQ37339817-97922CC6-27E5-4BFF-A8AE-BE19C01FAA36Q38967358-4B233E20-A03D-435A-A797-3B2DF6982450Q41835260-C33E7F42-C122-4A6F-9511-723B078BE071Q42562588-CEFF49B3-AF80-449E-950F-BECE6CA97941Q42992664-90CF8678-434C-4C37-A0E6-36A22413F0AAQ44866395-30C163C4-27A0-483E-B4E4-E504A4B65EA3Q45960735-2699E250-13CB-4D3B-93A9-F6A92A4C6B59Q47681527-3B7B69CB-BDE4-42DD-B24B-49FE2B99AE37Q51375327-DD042A74-5C0A-418F-B783-A3E6960FD835Q53223519-D2C1AFDA-C923-4D66-A5DE-B09B37AC449AQ53553600-89EB0E0E-B898-4BE9-AEF1-CF2630368366Q57591266-C393E494-2AF1-4462-B039-E03EE872F7AEQ58792844-F4AB460A-25E7-4993-AFF8-A08819D090FA
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Risk factors for progressive chronic kidney disease.
@ast
Risk factors for progressive chronic kidney disease.
@en
type
label
Risk factors for progressive chronic kidney disease.
@ast
Risk factors for progressive chronic kidney disease.
@en
prefLabel
Risk factors for progressive chronic kidney disease.
@ast
Risk factors for progressive chronic kidney disease.
@en
P1476
Risk factors for progressive chronic kidney disease.
@en
P2093
W Dana Flanders
William M McClellan
P304
P356
10.1097/01.ASN.0000070147.10399.9E
P433
P577
2003-07-01T00:00:00Z